Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

ConferenceBreast cancer vaccinelira-celPositive

AI Analysis

Summary

Anixa Biosciences will present at the 2026 Cantor Fitzgerald Global Healthcare Conference on its breast cancer vaccine, which met all Phase 1 primary endpoints with protocol-defined immune responses in 74% of participants, and its ovarian cancer CAR-T therapy lira-cel, which has advanced to the highest dose level in the fifth cohort.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Importance:5/10

Sentiment:

0.65

breast cancer vaccineovarian cancerCAR-T therapyPhase 1 dataimmunotherapyconference presentation

Related Companies

$ANIX

Read the original article

Published by PR Newswire Biotech on August 24, 2026 12:55 PM

Read Original